Impact of platelet to lymphocyte ratio and metabolic syndrome on the prognosis of colorectal cancer patients.

OBJECTIVE

The aim of this study was to evaluate the prognostic value of both platelet to lymphocyte ratio (PLR) and metabolic syndrome (MetS) in colorectal cancer (CRC) patients.

PATIENTS AND METHODS

We retrospectively enrolled 1,163 CRC patients. Preoperative values of PLR were stratified into three groups according to cut-off values of 120 and 220. The Kaplan-Meier analysis was used to calculate cumulative survival rate related to PLR and MetS. Cox proportional hazard regression models were used to analyze potential risk factors and the prognosis associated with PLR and MetS in CRC patients.

RESULTS

PLR was significantly higher in the MetS(+) group as compared to MetS(-) group (=0.039). An elevated PLR was significantly associated with mortality (=0.014), but not the existence of MetS (=0.235). In multivariate regression analysis, PLR was an independent risk factor for overall survival (OS) (=0.046). For the subgroup with a PLR >220, MetS was an independent predictor for both OS and disease-free survival (=0.039 and =0.047, respectively) by multivariate analysis adjusting for confounding covariates. In addition, the presence of MetS was associated with a 2-fold increased risk of mortality and tumor recurrences (hazard ratio [HR] =2.0 and HR =1.9, <0.05, respectively).

CONCLUSION

Preoperative PLR was associated with MetS in CRC patients. Testing for the combined presence of PLR and MetS could potentially improve the predictive accuracy of CRC prognosis.